Table 5.
Ratio and 95% CI of Observed to Expected Number of Deaths at Discharge Among 10,210 Individuals with COVID-19 Hospitalization and a History of Cancer, by Cancer Type
| Cancer type | Number of observed deaths | Number of expected deaths* | Ratio of observed to expected (95% CI) |
|---|---|---|---|
| Brain and other nervous system | <11 | Suppressed | 0.85 (0.39-1.62) |
| Breast | 267 | 366 | 0.73 (0.64-0.82) |
| Cervix uteri | 14 | 17 | 0.83 (0.45-1.40) |
| Colorectal | 207 | 233 | 0.89 (0.77-1.02) |
| Corpus uterus and NOS | 75 | 98 | 0.76 (0.60-0.96) |
| Esophagus | 12 | 10 | 1.14 (0.59-2.00) |
| Hodgkin lymphoma | 12 | 11 | 1.13 (0.58-1.97) |
| Kidney and renal pelvis | 98 | 105 | 0.94 (0.76-1.14) |
| Larynx | 15 | 18 | 0.85 (0.48-1.41) |
| Leukemias | 113 | 110 | 1.03 (0.85-1.24) |
| Liver and intrahepatic bile duct | 33 | 25 | 1.32 (0.91-1.86) |
| Lung and bronchus | 235 | 212 | 1.1 1 (0.97-1.26) |
| Melanoma | 46 | 72 | 0.64 (0.47-0.85) |
| Myeloma | 65 | 62 | 1.04 (0.80-1.33) |
| Non-Hodgkin lymphomas | 140 | 138 | 1.01 (0.85-1.19) |
| Oral cavity and pharynx | 36 | 41 | 0.88 (0.61-1.21) |
| Other malignancies of hematopoietic or lymphopoietic origin | 58 | 61 | 0.94 (0.72-1.22) |
| Ovary | 12 | 20 | 0.61 (0.32-1.07) |
| Pancreas | 24 | 22 | 1.07 (0.68-1.59) |
| Prostate | 532 | 552 | 0.96 (0.88-1.05) |
| Stomach | 27 | 31 | 0.88 (0.58-1.28) |
| Testis | <11 | Suppressed | 0.34 (0.04-1.24) |
| Thyroid | 37 | 55 | 0.67 (0.47-0.93) |
| Urinary bladder including in situ | 153 | 157 | 0.97 (0.83-1.14) |
NOS, not otherwise specified. * Number of expected COVID-19 hospitalizations was calculated using the age- and sex-specific proportions of deaths for all 10,210 cancers.